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Abstract
Purpose The purpose of the study was to evaluate
the efficacy of a topical form of a carbonic anhydrase
inhibitor (dorzolamide) on the foveal function and
thickness in the eye of a patient with enhanced S-cone
syndrome (ESCS) associated with macular cysts.
Methods Twenty-eight-year-old Polish man with
ESCS and macular cysts appearance in the right eye
was treated 3 times daily with 2.0 % dorzolamide
drops for the period time equal to 6 months. Monthly
controls included: best corrected distance visual acuity
(BCDVA-logMAR), foveal thickness (optical coher-
ence tomography, OCT) and foveal function (multi-
focal electroretinography, mfERG).
Results Before treatment, BCDVA in the right eye
was equal to 0.26 logMAR, improved to 0.1 logMAR
during the first 3 months and remained stable for the
next 3 months. After 6 months, foveal thickness
decreased (from 482 to 224 lm) and foveal function
improved (the amplitude of P1-wave density increased
from 34.8 to 107.3 nV/deg2) and was between the
ranges of normal values. Implicit time of P1-wave
remained prolonged.
Conclusions The results of our short-term study
suggest potential efficacy of topical dorzolamide
treatment in ESCS patients with macular cysts.
Keywords Macular cysts  Enhanced S-cone
syndrome  Foveal function and thickness  Topical
dorzolamide
Introduction
Enhanced S-cone syndrome (ESCS) first described in
1990 by Marmor et al. [1] is a rare, slowly progressive
autosomal recessive inherited retinal degenerative
disorder. In most cases of ESCS, NR2E3 gene
mutation is responsible for the disease development
and leads to abnormal cones and rods differentiation
[2]. Characteristic fundus changes usually progress
from subtle pigmentary changes with white dots in the
early stage to a more severe nummular pigmentary
deposition around the vascular arcades accompanied
by yellowish dots later on. Cystic macular changes
occur frequently, in about 50–75 % of cases [3, 4].
Enhanced S-cone syndrome is diagnosed on the
basis of characteristic clinical fundus changes and
pathognomonic features of the full-field electroreti-
nography (ERG). There were performed according to
the International Society for Clinical Electrophysiol-
ogy of Vision (ISCEV) standards such as the absence
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of rod response, morphologically similar waveforms
of scotopic and photopic responses to the standard
stimulus flashes (3.0 ERG) and flicker reduction [4, 5].
The S-cone ERG recording can be performed to
confirm the pathophysiologic origin of the disease (the
S-cone hyperactivity) and is characterized by abnor-
mally large and delayed waveforms (relative to those
with standard stimulation) [3].
Retinal pigment epithelium (RPE) function is
abnormal in ESCS retina [6], resulting in macular
cysts development. Dorzolamide (topical form of
carbonic anhydrase inhibitor) may improve RPE
metabolism by activating the pumping function and
consequently, it reduces intraretinal cysts and RPE
remains adherent to the retina [7, 8].
Only 3 case report studies [9–11] described efficacy
of topical (2.0 % dorzolamide) and/or oral (acetazol-
amide) carbonic anhydrase inhibitor in the treatment
of macular cysts associated with ESCS. In these 3
patients, increase in visual acuity associated with
normalization of foveal microanatomy (illustrated by
OCT) was observed. Treatment time in these studies
varied from 4 [9, 10] up to 27 months [11]. During the
follow-up, visual acuity, foveal thickness and structure
in each patient improved and remained stable. These
promising initial results were the reason to implement
dorzolamide therapy in a newly diagnosed ESCS
patient presented in this report (Table 1).
Case
A twenty-eight-year-old white male was sent to the
ophthalmology clinic with the suspicion of ESCS and
had following complaints: night vision problems since
the childhood and decreased visual acuity since
2 years in the left eye and most recently in the right
eye. Informed consent was obtained from the patient
before the examination.
Initially, the patient’s BCDVA was equal to 0.26 in
the right eye and 0.2 in the left eye on a logMAR scale
(early treatment diabetic retinopathy study chart).
Color vision (Farnsworth Panel-15 D) was normal in
both eyes. Fundus exam revealed white dots around
the vascular arcades accompanied by single black
flecks. Optic disc and vessels were normal. Clinical
features of macular cysts were noticed in both eyes
(Fig. 1). Macular cysts appearance was confirmed by
the OCT test (Zeiss Stratus OCT, Humphrey Instru-
ments model 3000, Carl Zeiss Inc, Dublin, CA, 2007).
The cystoid spaces appeared as hyporeflective spaces,
interspersed with high-signal septae which repre-
sented bridging retinal elements in both eyes. Loss
of the normal foveal depression was observed in the
right eye (Fig. 2). In the left eye, foveal contour
became even convex and dome shaped, as previously
described in the literature [6]. Fluorescein angiogram
showed absence of any detectable leakage of the dye in
the macular area in either eye.
Fig. 1 Fundus photographs, the right and left eye of the
28-year-old man with ESCS
Table 1 .
VA logMAR ETDRS FT (lm) P1 density (nV/deg2) Implicit time (ms)
M ± SD Range Med Range M ± SD Range
Normal values 0.0 212 ± 20 192–232 134.5 106.8–148.2 39.2 ± 2.1 35–43.3
M mean, SD standard deviation, Med median
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The ERG (ISCEV) [12] was recorded, using
Burian–Allen bipolar electrodes (UTAS-E2000,
LKC, USA). It showed the absence of rod response,
reduced and delayed waveforms in response to white
flash (0 dB), both in scotopic and photopic conditions,
reduced and delayed flicker recording (Fig. 3). In the
S-cone ERG recordings, blue stimulus (455 nm, 5 ms,
80 cd/m2, 16 cd s/m2) was used in the orange back-
ground (590 nm, 560 cd/m2). Parameters were similar
to those performed by Audo et al. [3]. The recordings
presented hyper-normal and delayed a- as well as b
waves. In mfERG (ISCEV) [13] (RetiScan system,
Roland Consult, Germany, 2009), delayed and
reduced P1-wave amplitudes were observed in all six
analyzed concentric rings. NR2E3 gene sequencing
was not performed, because it is not necessary for
ESCS diagnosis.
The patient was treated with topical form of 2.0 %
dorzolamide 3 times daily for 6 months. Initially, it
was applied to both eyes. Left eye treatment was
discontinued after 1 month because of inefficacy and
cystoid macular changes progression. The probable
reason of the left eye treatment failure was prolonged
macular cysts appearance, which caused profound and
irreversible RPE and cone photoreceptors dysfunction.
Examinations that were performed after 1st, 2nd,
3rd, 4th and 6th months of the treatment consisted of:
BCDVA, mfERG and OCT tests (5th month exami-
nation failed due to the absence of the patient). The
tenets of the Declaration of Helsinki were followed.
Informed consent was obtained after the details of the
procedures had been fully explained.
BCDVA increased gradually during the treatment
from 0.26 to 0.22 logMAR at the 1st, to 0.14 logMAR
at the 2nd and to 0.1 logMAR at the 3rd follow-up
examination (Fig. 4). BCDVA in the right eye
remained stable during the next 3 months of treatment.
Except the 3rd follow-up examination, central retinal
function, presented by P1 wave response density in
mfERG improved and recover to normal value during
6 months follow-up. One of the possible explanations
of this was unsystematic use of the drops in the 3rd
month, which was confirmed by the patient. P1 wave
implicit time during first 2 months of treatment
shortened, but then it returned to the value before the
treatment (Fig. 4).
The improvement of BCDVA in the right eye
corresponded with foveal thickness reduction from
482 lm initially to 359 lm at the 1st and to 226 lm at
the 2nd follow-up visit (Fig. 2). At this point, intraretinal
Fig. 2 Optical coherence tomography (OCT) images (above) and mfERG recordings (below) of the right eye of the 28-year-old man
with ESCS before and after a 6-month treatment with topical dorzolamide in comparison with the age-matched healthy control
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cysts were completely absorbed. Foveal thickness
remained unchanged for the next 3 follow-up visits.
Discussion
The main reason behind the decreased visual acuity in
ESCS patients is cystoid changes in macular region.
Macular cysts early diagnosis may be of great value
for ESCS patients, when at least partial RPE function
is preserved. It is possible that by using topical
dorzolamide, which provides an increased RPE pump-
ing function and in consequence intraretinal fluid
absorption, restoration of normal foveal morphology
can be obtained and even in some cases, visual acuity
may improve [9–11].
An extracellular membrane-bound carbonic anhy-
drase (CA XIV) was shown to be present in brain and
retina (astrocytes, Muller cells and RPE). Carbonic
anhydrase XIV is the target of carbonic anhydrase
inhibitors that enhance subretinal fluid absorption in
macular edema [14]. Carbonic anhydrase inhibitors
usefulness was proven in the treatment of macular
cystoid changes associated with diseases such as
retinitis pigmentosa [15–18], choroideremia [19] and
X-linked retinoschisis [20].
To our best knowledge, this is the third case report
study describing topical dorzolamide efficacy in
macular cysts management in the ESCS patient, with
the longest follow-up period equal to 6 months.
Dorzolamide treatment was applied, because we
assumed that cystoid macular spaces were filled with
endogenous interstitial retinal fluid undetectable to
fluorescein angiography testing. Obtained results are
in agreement with previously published data [9–11],
which presented the visual acuity improvement and
foveal structure normalization after dorzolamide
treatment.
For the 1st time, mfERG was used to evaluate
foveal function during the topical dorzolamide
Fig. 3 Full-field ERG of
the ESCS patient
244 Doc Ophthalmol (2013) 126:241–246
123
treatment of macular cysts in ESCS. MfERG is a well-
known technique reflecting functional mapping of the
retina including foveal region, especially bipolars and
cone photoreceptors [21]. To date, to estimate the
macular cysts treatment efficacy of ESCS patients
visual acuity, retinal thickness measurements (OCT),
contrast sensitivity and microperimetry were used [9–
11]. However, visual acuity examination is not an
accurate function test. The results of visual acuity
measurements are subjective and allow only to
estimate retinal function of about 1 central angle
degree. Hence, visual acuity examination is not
precise enough to estimate retinal function from
retinal regions covering macular cysts, which usually
surpasses 1 angle degree. That is why we decided to
evaluate the retinal function with mfERG. Results of
mfERGs provided in this case useful information that
visual acuity and foveal thickness improvement cor-
responded with partial increase in foveal function.
Assessment of foveal region function with mfERG
was previously described in patients with epiretinal
membrane, retinitis pigmentosa, diabetic macular
edema, uveitic macular edema and others [22–24].
The results of our study suggest that the use of
topical form of carbonic anhydrase inhibitor should be
consider for a treatment of macular cysts associated
with ESCS.
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